We are live on ! Find out more
PPCB icon

Propanc Biopharma
PPCB

3 hedge funds and large institutions have $71.5K invested in Propanc Biopharma in 2026 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

172% more capital inflows, than outflows

Capital inflows: $91K | Capital outflows: $33.5K

3.61% less ownership

Funds ownership: 3.61% → 0% (-3.6%)

50% less funds holding

Funds holding: 6 → 3 (-3)

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

Holders
3
Holders Change
-3
Holders Change %
-50%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
–
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
+$42.8K
2
Citadel Advisors
Citadel Advisors
Florida
+$26.1K
3
HRT Financial
HRT Financial
New York
+$22.1K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$19.4K
2
Marex Group
Marex Group
-$7.18K
3
Virtu Financial
Virtu Financial
New York
-$4K
4
SCA
Sassicaia Capital Advisers
New York
-$1.7K
5
XTX Topco
XTX Topco
Cayman Islands
-$1.28K

PPCB Hedge Fund Activity: Q2 2026 in Review

3 of the 8,376 institutional investors tracked by Wall St. Rank reported a position in Propanc Biopharma (PPCB) for Q2 2026, worth a combined $71.5K — up 47% from $48.7K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of PPCB and 2 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was Jane Street, adding an estimated $42.8K. The largest seller was UBS Group, exiting entirely with an estimated $19.4K sold.

  • 3 institutional investors held Propanc Biopharma (PPCB) as of Q2 2026, down from 6 in Q1 2026.
  • Funds reported $71.5K of Propanc Biopharma stock for Q2 2026, up 47% quarter-over-quarter.
  • 2 funds opened new Propanc Biopharma positions in Q2 2026 and 5 closed out, a net change of -3 holders.
  • The largest Propanc Biopharma buyer in Q2 2026 was Jane Street, an estimated $42.8K added.
  • The largest Propanc Biopharma seller in Q2 2026 was UBS Group, an estimated $19.4K sold.

Based on aggregated 13F filings for Q2 2026.